Sandoz Jumps 7% on Biosimilar Surge, H1 Revenue Beats Forecast

Sandoz reported first-half 2026 net sales of $3.01 billion on August 5, narrowly beating analyst consensus of $2.99 billion. Biosimilar revenue jumped 22% at constant currencies, now accounting for 33% of total sales. The stock rallied 7% in early trading as management highlighted a “golden decade” ahead, with $650 billion in drug patents set to expire over the next ten years.

Biosimilars drive record growth in North America

Biosimilar net sales rose 22% at constant currencies in the first half, with North America posting exceptional 47% growth. The region benefited from June 2025 launches of bone disease drug Wyost and osteoporosis medication Jubbonti. Eye medication Afqlir boosted European sales, while Rixathon, a biosimilar of Roche’s cancer and rheumatism drug MabThera/Rituxan, drove growth in international markets.

Generics stabilize after weak start

The generics division, which comprises 67% of revenue, posted $3.9 billion in sales for the first half, down 1% on a currency-adjusted basis. Antibiotic active ingredient supply headwinds in the first quarter weighed on results. However, the segment returned to growth in Q2 with 1% currency-adjusted increases, allowing Sandoz to stabilize performance and confirm its full-year guidance.

Profitability expands despite legal pressures

Core EBITDA reached $1.2 billion with a margin of 20.9%, up from 20.0% in the prior-year period. The company faced legal cost headwinds during the period, yet margins still expanded. CEO Richard Saynor noted the company is “extremely well positioned” to capitalize on the wave of patent expirations, with $650 billion in products due to lose exclusivity over the next decade.

GLP-1 opportunity emerges as next growth driver

Sandoz received its first approval in Brazil for a multi-dose disposable pen version of semaglutide, a diabetes and obesity drug. The U.S. Food and Drug Administration agreed in June to review two generic tirzepatide GLP-1 formulations. These approvals position Sandoz to compete in the rapidly expanding diabetes and obesity market, a major opportunity for both biosimilars and generic drugs.

Final Thoughts

Sandoz’s biosimilar momentum and beat on H1 sales signal strong execution in a favorable patent-expiration cycle. With generics stabilizing and margins expanding despite legal costs, the stock’s 7% rally reflects investor confidence in management’s “golden decade” thesis. The GLP-1 pipeline adds another growth vector.

FAQs

Disclaimer:

The content shared by Meyka AI PTY LTD is solely for research and informational purposes.  Meyka is not a financial advisory service, and the information provided should not be considered investment or trading advice.